← Back to Clinical Trials
Recruiting Phase 4 NCT06433310

Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study

Trial Parameters

Condition Gut Microbiome
Sponsor Weill Medical College of Cornell University
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 20
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-10-17
Completion 2027-12-17
Interventions
L-Phenylalanine 500 mg Veg Capsule product

Brief Summary

The purpose of this study is to explore how the dietary supplement L-Phenylalanine affects the production of the metabolite phenylpropionic acid (PPA) and changes fungal populations of the gut microbiome.

Eligibility Criteria

Inclusion Criteria: * Male or female adults over the age of 18 years Exclusion Criteria: * History of a diagnosis of any gastrointestinal condition, such as inflammatory bowel syndrome or disease * Antibiotic usage within the past two weeks * Antifungal usage within the past month * Allergy to L-Phenylalanine or individuals with phenylketonuria (PKU) * Adults taking medications known to interact with L-phenylalanine supplements, such as Monoamine Oxidase Inhibitors (MOAI), L-DOPA, and some antipsychotic drugs (complete and extensive drug list will be provided to interested participants during screening) * Pregnant or nursing women

Related Trials